IN2014CN04615A - - Google Patents
Info
- Publication number
- IN2014CN04615A IN2014CN04615A IN4615CHN2014A IN2014CN04615A IN 2014CN04615 A IN2014CN04615 A IN 2014CN04615A IN 4615CHN2014 A IN4615CHN2014 A IN 4615CHN2014A IN 2014CN04615 A IN2014CN04615 A IN 2014CN04615A
- Authority
- IN
- India
- Prior art keywords
- human ctgf
- anti human
- seq
- amino acid
- acid sequence
- Prior art date
Links
- 101000777550 Homo sapiens CCN family member 2 Proteins 0.000 abstract 5
- 102000047612 human CCN2 Human genes 0.000 abstract 5
- 125000003275 alpha amino acid group Chemical group 0.000 abstract 2
- 208000007342 Diabetic Nephropathies Diseases 0.000 abstract 1
- 230000027455 binding Effects 0.000 abstract 1
- 230000015572 biosynthetic process Effects 0.000 abstract 1
- 208000020832 chronic kidney disease Diseases 0.000 abstract 1
- 208000033679 diabetic kidney disease Diseases 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 208000017169 kidney disease Diseases 0.000 abstract 1
- 238000006386 neutralization reaction Methods 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/475—Growth factors; Growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
- C07K2317/41—Glycosylation, sialylation, or fucosylation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Toxicology (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Urology & Nephrology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2011281811 | 2011-12-22 | ||
| PCT/JP2012/083206 WO2013094723A1 (ja) | 2011-12-22 | 2012-12-21 | 新規抗ヒトｃｔｇｆ抗体 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IN2014CN04615A true IN2014CN04615A (enrdf_load_stackoverflow) | 2015-09-18 |
Family
ID=48668601
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IN4615CHN2014 IN2014CN04615A (enrdf_load_stackoverflow) | 2011-12-22 | 2012-12-21 |
Country Status (16)
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN109824777A (zh) * | 2019-03-15 | 2019-05-31 | 辽宁何氏医学院 | 一种具有抑制玻璃体视网膜纤维化病变作用的单克隆抗体及其制备方法和应用 |
| US20200369759A1 (en) | 2019-05-23 | 2020-11-26 | Fibrogen, Inc. | Methods of treatment of muscular dystrophies |
| MX2021014803A (es) * | 2019-06-04 | 2022-01-18 | Jiangsu Hengrui Medicine Co | Anticuerpo anti-factor de crecimiento de tejido conectivo y aplicacion del mismo. |
| US20230416352A1 (en) * | 2020-12-03 | 2023-12-28 | Jiangsu Hengrui Pharmaceuticals Co., Ltd. | Pharmaceutical composition comprising anti-connective tissue growth factor antibody |
| JPWO2023238845A1 (enrdf_load_stackoverflow) | 2022-06-07 | 2023-12-14 | ||
| KR20250097820A (ko) | 2022-10-31 | 2025-06-30 | 아스텔라스세이야쿠 가부시키가이샤 | Toll양 수용체 7/8 듀얼 아고니스트 화합물을 포함하는 항체 약물 복합체 |
| WO2024188179A1 (zh) * | 2023-03-10 | 2024-09-19 | 上海济煜医药科技有限公司 | 一种靶向ctgf的抗体或其抗原结合片段及其应用 |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE8808645U1 (de) | 1988-07-06 | 1988-08-25 | Hofer, Daniel, 7730 Villingen-Schwenningen | Anzeigeeinrichtung für Feuerlöscher |
| DE69433422T2 (de) | 1993-03-11 | 2004-09-16 | Juridical Foundation The Chemo-Sero-Therapeutic Research Institute | Monoklonaler anti-hiv antikörper |
| EP1043335A4 (en) | 1997-12-25 | 2005-08-31 | Japan Tobacco Inc | MONOCLONAL ANTIBODY AGAINST THE BIND WEIGHT GROWTH FACTOR AND ITS MEDICAL USES |
| JP4537507B2 (ja) | 1997-12-25 | 2010-09-01 | アムジェン インコーポレイテッド | 結合組織増殖因子に対するモノクローナル抗体及びその医薬用途 |
| AU775391B2 (en) | 1998-12-14 | 2004-07-29 | Fibrogen, Inc. | Connective tissue growth factor fragments and methods and uses thereof |
| US7115390B1 (en) | 1998-12-14 | 2006-10-03 | Fibrogen, Inc. | Connective tissue growth factor fragments and methods and uses thereof |
| US6596541B2 (en) | 2000-10-31 | 2003-07-22 | Regeneron Pharmaceuticals, Inc. | Methods of modifying eukaryotic cells |
| US7405274B2 (en) * | 2003-06-04 | 2008-07-29 | Fibrogen, Inc. | Connective tissue growth factor antibodies |
| JP2009067678A (ja) * | 2005-12-07 | 2009-04-02 | Nihon Nosan Kogyo Kk | 結合組織増殖因子に対する抗体又はそれを含む組成物 |
| US7608693B2 (en) | 2006-10-02 | 2009-10-27 | Regeneron Pharmaceuticals, Inc. | High affinity human antibodies to human IL-4 receptor |
-
2012
- 2012-12-21 CN CN201280063995.5A patent/CN104011206B/zh not_active Expired - Fee Related
- 2012-12-21 BR BR112014015405A patent/BR112014015405A2/pt unknown
- 2012-12-21 TW TW101148989A patent/TW201333034A/zh unknown
- 2012-12-21 ES ES12860742.1T patent/ES2665851T3/es active Active
- 2012-12-21 MX MX2014007681A patent/MX345019B/es active IP Right Grant
- 2012-12-21 US US14/367,081 patent/US9587015B2/en not_active Expired - Fee Related
- 2012-12-21 CA CA2859627A patent/CA2859627A1/en not_active Abandoned
- 2012-12-21 JP JP2013550349A patent/JP6040943B2/ja not_active Expired - Fee Related
- 2012-12-21 KR KR1020147020039A patent/KR20140107507A/ko not_active Abandoned
- 2012-12-21 PL PL12860742T patent/PL2796550T3/pl unknown
- 2012-12-21 AR ARP120104933A patent/AR089425A1/es unknown
- 2012-12-21 EP EP12860742.1A patent/EP2796550B1/en active Active
- 2012-12-21 WO PCT/JP2012/083206 patent/WO2013094723A1/ja active Application Filing
- 2012-12-21 PT PT128607421T patent/PT2796550T/pt unknown
- 2012-12-21 EA EA201491240A patent/EA029290B1/ru not_active IP Right Cessation
- 2012-12-21 IN IN4615CHN2014 patent/IN2014CN04615A/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| PT2796550T (pt) | 2018-04-18 |
| EP2796550B1 (en) | 2018-02-28 |
| KR20140107507A (ko) | 2014-09-04 |
| MX345019B (es) | 2017-01-11 |
| US20140343258A1 (en) | 2014-11-20 |
| EP2796550A1 (en) | 2014-10-29 |
| PL2796550T3 (pl) | 2018-08-31 |
| WO2013094723A1 (ja) | 2013-06-27 |
| BR112014015405A2 (pt) | 2017-06-13 |
| CN104011206A (zh) | 2014-08-27 |
| JPWO2013094723A1 (ja) | 2015-04-27 |
| US9587015B2 (en) | 2017-03-07 |
| AR089425A1 (es) | 2014-08-20 |
| EP2796550A4 (en) | 2015-08-19 |
| ES2665851T3 (es) | 2018-04-27 |
| EA201491240A1 (ru) | 2014-11-28 |
| JP6040943B2 (ja) | 2016-12-07 |
| CN104011206B (zh) | 2017-03-08 |
| TW201333034A (zh) | 2013-08-16 |
| CA2859627A1 (en) | 2013-06-27 |
| MX2014007681A (es) | 2014-11-25 |
| EA029290B1 (ru) | 2018-03-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IN2014CN04615A (enrdf_load_stackoverflow) | ||
| NZ610734A (en) | Human antibodies to the glucagon receptor | |
| WO2009048537A3 (en) | Humanized antibody | |
| NZ706377A (en) | Il-6 antagonists and uses thereof | |
| SI2771031T1 (en) | Humanized antibodies that recognize alpha-synuclein | |
| EA201201227A1 (ru) | Бипаратопные а-бета-связывающие полипептиды | |
| EA201301107A1 (ru) | Моноклональные антитела против ингибитора пути тканевого фактора (tfpi) | |
| MX348577B (es) | Composicion farmaceutica para el tratamiento y/o prevencion de cancer. | |
| BR112014002613A2 (pt) | anticorpo, composição farmacêutica, combinação farmacêutica para tratamento e/ou prevenção de câncer, dna e método | |
| EA201490622A1 (ru) | Агенты, связывающие фактор роста эндотелия сосудов (vegf)/дельта-подобный лиганд (dll4), и их применение | |
| NZ706986A (en) | Human antibodies to human tnf-like ligand 1a (tl1a) | |
| RU2012137498A (ru) | Фармацевтическая композиция для лечения и/или профилактики рака | |
| WO2009048538A3 (en) | Use of anti-amyloid beta antibody in ocular diseases | |
| EA201490433A1 (ru) | Новое антитело против ngf человека | |
| EA033387B1 (ru) | СТАБИЛИЗИРОВАННЫЕ СОСТАВЫ, СОДЕРЖАЩИЕ АНТИТЕЛА ПРОТИВ Ang-2 | |
| EA201070553A1 (ru) | Антитела к гепцидину и варианты их применения | |
| RU2013140625A (ru) | Антитела против ангиопоэтина-2 человека | |
| WO2013120012A3 (en) | Cdim binding proteins and uses thereof | |
| MY160892A (en) | Antibodies to ccr2 | |
| WO2014012007A3 (en) | Rspo3 binding agents and uses thereof | |
| PH12013501456A1 (en) | Use of anti~amyloid beta antibody | |
| EA201490745A1 (ru) | Полипептиды антител, которые вызывают антагонизм cd40l | |
| MX2012000316A (es) | Anticuerpos humanizados para el receptor 2 tipo toll y usos de los mismos. | |
| EA201290849A1 (ru) | Оптимизированные моноклональные антитела против ингибитора пути тканевого фактора (tfpi) | |
| EA201491235A1 (ru) | Варианты полипептидов fc-pol с улучшенным связыванием неонатального рецептора fc |